Published April 26, 2026 | The Law Office of Shay Aaron Gilmore| California Cannabis & Hemp Business Law
On April 22, 2026, Acting Attorney General Todd Blanche signed the most consequential federal cannabis order in more than five decades. The order immediately moves both FDA-approved cannabis products and state-regulated medical cannabis products from Schedule I to Schedule III of the Controlled Substances Act (CSA). At the same time, it launches an expedited administrative hearing — beginning June 29, 2026 — to determine whether broader rescheduling of all marijuana, including adult-use products, should follow.
For California medical cannabis licensees and investors, this is not an abstract federal development. It is a live, operational event with immediate legal, tax, corporate, and compliance consequences. This post breaks down what changed, what did not, what is still unresolved — and specifically what California M-license operators and their advisors need to do right now.
As discussed in our prior post Marijuana Rescheduling, If It Happens, Will Be Incremental Progress — Still Not the Answer, and followed up in California Cannabis M&A in 2026: Rescheduling Momentum, Hemp Bans, and State Integration Collide, rescheduling was never going to be a cure-all. What April 22, 2026 delivered is real but narrow — and the narrowness is exactly what California operators need to understand.
How We Got Here
The rescheduling process dates back to October 2022, when President Biden directed HHS and the DEA to review marijuana’s CSA scheduling. In August 2023, HHS recommended Schedule III, finding that marijuana has a currently accepted medical use and a lower abuse potential than Schedule I or II substances. The DEA published a Notice of Proposed Rulemaking in May 2024, attracting more than 42,000 public comments. Hearings were postponed multiple times — first due to procedural challenges, then due to a stay pending interlocutory appeal.
The process appeared stalled until December 18, 2025, when President Trump signed Executive Order 14370 directing the Attorney General to “expedite and complete” the rescheduling process. Rather than restart the cumbersome notice-and-comment rulemaking, Acting AG Blanche invoked 21 U.S.C. § 811(d)(1), which permits the Attorney General to schedule substances by order when necessary to comply with U.S. obligations under the 1961 Single Convention on Narcotic Drugs — without the full procedural requirements otherwise imposed by the CSA. This treaty-based authority allowed the administration to act immediately.
Critically, the order does not cover all marijuana. It covers two categories only: FDA-approved drug products containing delta-9-THC, and marijuana handled under a qualifying state-issued medical marijuana license. All other marijuana — including adult-use cannabis sold under a state recreational license — remains Schedule I pending the outcome of the June 29 hearing. Hemp and synthetically derived THC are expressly excluded.
California’s Dual-License Structure: The Essential Starting Point
To appreciate what this order does and does not do for California operators, the state’s parallel license structure under the Medicinal and Adult Use Cannabis Regulation and Safety Act (MAUCRSA) is the essential starting point.
Under MAUCRSA, the Department of Cannabis Control (DCC) issues two parallel license designations across all activity categories — cultivation, manufacturing, distribution, retail, testing, and event organizers. An M-license (medicinal designation) authorizes a licensee to engage only in medicinal commercial cannabis activity. An A-license (adult-use designation) authorizes activity only in the adult-use market. A business may hold both designations on the same licensed premises, provided it holds both designations for the identical type of activity.
This bifurcation — maintained since MAUCRSA’s 2017 enactment — turns out to be precisely the distinction that determines who receives federal relief under the April 22 order. The federal order tracks state-licensing categories: it reschedules marijuana products subject to a qualifying state-issued medical marijuana license, and a California M-license fits squarely within that definition. A California A-license does not.
Pure M-license operators — those holding only medical designations across their operations — are unambiguously covered. Dual-license operators, sometimes referred to as mixed-use or MSO-affiliated entities, occupy far more complicated ground, addressed in detail below.
The Tax Transformation: Section 280E Relief Is Real and Effective January 1, 2026
The single largest immediate benefit of rescheduling for California M-license operators is the elimination of the Section 280E deduction disallowance.
Internal Revenue Code § 280E prohibits any deduction or credit for ordinary and necessary business expenses incurred in the “trafficking” of a Schedule I or II controlled substance. Because the IRS treated state-licensed cannabis businesses as traffickers in a Schedule I substance, California operators could not deduct payroll, rent, utilities, marketing, professional services, or any other standard operating expense at the federal level — only cost of goods sold (COGS) remained deductible. The result was effective federal tax rates commonly exceeding 70% for California dispensaries and supply-chain operators.
California partially addressed this disparity through Assembly Bill 37 in 2019, which decoupled state tax law from IRC § 280E, allowing MAUCRSA licensees to take ordinary deductions on their California returns. But the federal burden remained crushing — particularly for California operators who also face some of the highest combined state and local cannabis taxes in the country.
The April 22 order eliminates 280E’s reach over qualifying medical operators. The Treasury Department and IRS confirmed the same day that rescheduling “removes section 280E as a bar to claiming deductions and credits” for qualifying businesses and announced forthcoming guidance. Treasury further confirmed that for § 280E purposes, rescheduling applies for a business’s full taxable year that includes the effective date — meaning January 1, 2026 for calendar-year filers.
This is not a future benefit contingent on further rulemaking. For California M-license operators, the 280E burden has been lifted for the full 2026 tax year. The practical cash-flow impact is substantial: the broader industry is estimated to have been absorbing $2.3 billion in excess federal taxes annually above what it would pay as an ordinary business.
Retroactive Relief: Possible but Not Guaranteed
The order also includes precatory language encouraging — though not mandating — the Secretary of the Treasury to consider retrospective relief from § 280E for taxable years in which a state licensee operated under a state medical marijuana license. This language is aspirational, not legally binding. As one detailed analysis notes, the IRS is not obligated to comply, and operators should not amend prior returns or book corresponding assets until the IRS formally confirms the availability, scope, and mechanics of any look-back period. That said, California M-license operators should begin documenting prior-year expenses now to move quickly if Treasury guidance confirms retroactive applicability.
DEA Registration: A New Federal Compliance Obligation with Teeth
The DEA registration requirement is where this order becomes both the most operationally transformative and the most legally technical for California operators. It is not a benefit layered on top of existing operations. It is a new federal compliance obligation that determines whether an operator can legitimately access Schedule III status — and all of the benefits that accompany it.
What the Requirement Actually Means
The CSA has always required registration with the DEA Diversion Control Division for manufacturers, distributors, and dispensers of any controlled substance, including those in Schedule III. Before April 22, 2026, this requirement had no practical enforcement path against state-licensed medical cannabis operators — their activity was federally illegal under Schedule I, and the DEA’s accommodation of state cannabis markets was purely a matter of prosecutorial discretion. Rescheduling changes the legal architecture fundamentally: state-licensed medical operators are now engaged in a federally recognized activity, and federal law requires that recognized activity to be registered.
The order codifies a new registration pathway under 21 C.F.R. § 1301.13(k) — titled “Medical marijuana registrations” — which directs the DEA to establish an expedited review process for entities holding state medical marijuana licenses seeking registration as manufacturers, distributors, or dispensers. This is not aspirational guidance. It is now codified in the Code of Federal Regulations. And critically, the order is explicit: operating without DEA registration while handling Schedule III-controlled substances is a federal violation.
The practical implication for California operators is significant: to be entitled to the benefits of Schedule III status — most importantly, 280E relief — an M-license operator must obtain and maintain federal DEA registration. An operator who continues business-as-usual under their DCC M-license without filing for DEA registration is not simply missing an optional federal benefit; they are operating outside federal law in a newly codified way.
The 60-Day Window: Why It Is Critical
State-licensed medical marijuana licensees that submit DEA registration applications within 60 days of Federal Register publication — by approximately June 22, 2026 — may continue operating under their state license while the DEA processes the application. This “interim operating authority” provision protects operators from the disruption of having to cease operations while awaiting federal processing. Operators who miss this window forfeit the protection and face the risk that their Schedule III activity may be federally unauthorized during any gap between application and approval.
The DEA has committed to processing applications filed within the 60-day window within six months of receipt. For applications filed after that window, no such processing timeline commitment applies. The practical message: file within 60 days, or accept the risk of an uncertain processing timeline during which your federal compliance status is ambiguous.
Why a California M-License Is Uniquely Valuable — and the Public-Interest Factors That Can Still Block You
The new regulation provides that a state medical marijuana license “shall constitute conclusive evidence that the applicant is authorized under state law to engage in the activity for which registration is sought.” This is a significant legal accommodation. Under standard DEA registration procedures, an applicant must independently establish state-law authorization, and the DEA has substantial discretion to investigate and question that showing. The April 22 order eliminates that ambiguity for California M-license holders: the license is, by regulation, conclusive.
However, conclusive state authorization does not guarantee federal registration. The DEA must register the applicant unless doing so would be inconsistent with the public interest under 21 U.S.C. § 823 or with the requirements of the Single Convention. The § 823 public interest factors include:
- Maintenance of effective controls against diversion of controlled substances;
- Compliance with applicable state and local laws;
- Prior conviction record relating to manufacture, distribution, or dispensing of controlled substances;
- Lack of experience in the distribution of controlled substances; and
- Other factors relevant to and consistent with public health and safety.
For California operators, the most significant factor is compliance with applicable state and local laws. A DCC license with a clean compliance history — no suspensions, no enforcement actions, no unresolved violations — satisfies this factor readily. But operators with prior DCC disciplinary history, unresolved local permit violations, or any federal criminal exposure should carefully assess their § 823 posture before filing, not after. A denial triggered by public-interest concerns creates a federal record that is substantially more damaging than simply not filing.
Historical DEA precedent on this point is sobering: when the DEA reviewed manufacturer registrations for research cannabis in 2021, it noted that conducting cannabis activities compliant with state law but in violation of the CSA “may constitute grounds to deny an applicant’s registration” under the public-interest factors — citing such activity as relevant to the “promotion and protection of public health and safety.” While the new framework is designed to accommodate qualifying state licensees, the public interest factors remain live legal criteria that operators must treat as such.
Registration Is Location-Specific
A frequently overlooked aspect of DEA registration mechanics is that registration is tied to each principal place of business — each licensed premises where controlled substances are stored, administered, or dispensed requires a separate DEA registration. For California operators with multiple licensed locations — a common structure among vertically integrated businesses and those holding cultivator and retailer licenses at separate premises — this means a separate DEA registration application for each location.
This has direct compliance budget implications. A California operator with a licensed cultivation facility in Humboldt County and two licensed retail dispensaries in the Bay Area must file three separate DEA registration applications, each tied to the DCC license for that specific premises. Operators with multi-site portfolios need to inventory their licensed locations and plan registration filings accordingly — and within the 60-day window.
The Automatic Suspension Linkage: A New Federal Risk Tied to DCC Compliance
The April 22 order includes a provision that the DEA registration issued under the § 1301.13(k) expedited pathway is automatically suspended if the underlying California M-license is suspended, revoked, or expires. This is one of the most practically significant provisions in the entire order for California operators and their compliance counsel.
Before rescheduling, a DCC enforcement action — a license suspension, a notice of violation, or even an administrative lapse in renewal — was a purely state-level event. Federal law provided no corresponding benefit to suspend; the operator was already in a legally ambiguous federal position regardless of state compliance status. After rescheduling, the calculus is fundamentally different. A California M-license holder who obtains DEA registration now has a federal benefit that tracks DCC license status in real time. A state enforcement action that results in even a temporary DCC suspension triggers automatic federal registration suspension — meaning the operator’s Schedule III status and entitlement to 280E relief are simultaneously interrupted.
The implications for DCC regulatory compliance are substantial:
- License renewals must be timely. A DCC license that lapses due to a missed renewal filing, a bond coverage gap, or a delayed local permit renewal can trigger automatic federal suspension of the DEA registration. California operators are accustomed to state license renewals as administrative calendar items. They are now federal compliance events.
- DCC enforcement actions have federal consequences. An operator facing a DCC notice of proposed action, a license suspension, or a regulatory investigation must now assess the potential federal fallout in addition to the state consequences. Regulatory compliance counsel must communicate the federal suspension risk to clients engaged in DCC proceedings.
- Ownership change compliance has heightened stakes. DCC regulations require notification of ownership changes within 14 days and impose compliance obligations throughout the change process. If a change-of-ownership process creates a lapse or ambiguity in the DCC license during which the license could be deemed suspended, the DEA registration may be affected. Operators and counsel should structure ownership transitions to avoid any gap in DCC license status.
The automatic suspension linkage makes DCC license compliance not just a state business-preservation issue, but a federal one. For California M-license operators who have obtained DEA registration, the quality and currency of their DCC compliance program is now directly tied to their federal regulatory status.
Schedule III Compliance Obligations That Come with Registration
Obtaining DEA registration does not simply confer federal authorization — it subjects registrants to Schedule III compliance requirements under the CSA and DEA regulations. The April 22 order incorporates state compliance systems where possible, but federal requirements are additive, not displaced. Under the order, registered California M-license operators must comply with:
- Recordkeeping: Schedule III registrants are subject to DEA recordkeeping requirements, though the order directs the Administrator to accept state-required records, forms, and reports to the maximum extent permissible under federal law. California DCC recordkeeping systems — track-and-trace via Metrc — should substantially satisfy federal requirements, but operators should verify that their Metrc records are current and audit-ready before filing.
- Security standards: Registrants may generally rely on state-law physical-security requirements in lieu of otherwise applicable federal standards, subject to limited qualifications. California DCC security regulations are generally consistent with CSA Schedule III standards, but operators should confirm that any pending security upgrades or DCC compliance notices are resolved.
- Labeling and packaging: Registered operators must include the federal warning required by 21 U.S.C. § 825(c) where applicable, in addition to California DCC labeling requirements. Review of product labels for compliance with both state and federal requirements is now required for all M-licensed products.
- Disposal: State-authorized disposal procedures generally suffice under the order, but operators should document their disposal protocols to demonstrate compliance with both DCC and federal standards.
- Import/export permits: The order amends 21 C.F.R. Part 1312 to add an import/export permit requirement for Schedule III marijuana. Any California operator currently engaged in or contemplating interstate product movement must account for this permit requirement.
- The Single Convention nominal-price mechanism: State-licensed registrants are subject to a nominal-price purchase-and-resale arrangement designed to satisfy Article 23 of the Single Convention on Narcotic Drugs. Cultivators registering as manufacturers should understand this mechanism and its operational implications before completing registration.
The “Practitioner” Registration Category for Dispensaries
The order introduces an additional registration category relevant to California dispensaries. Entities that transfer Schedule III marijuana to patients — including California M-licensed retail dispensaries — must register with the DEA as “practitioners” under 21 U.S.C. § 823(g). This is a distinct registration category from the manufacturer or distributor registration, and the order makes clear that a practitioner registration does not authorize possession or dispensing of Schedule I controlled substances — meaning it does not extend to the adult-use inventory a dual-license dispensary also holds.
For California dual-license retail operators, this creates a layered registration question: the dispensary entity needs a practitioner DEA registration to cover its M-license dispensing activity, and continued state-only authorization (with no DEA registration) for its A-license adult-use activity. Inventory, recordkeeping, and physical custody of product must be maintained consistent with these different legal statuses simultaneously.
The Dual-License Problem: California’s Most Complex Compliance Challenge
Perhaps the most practically urgent compliance question in California concerns operators who hold both M-license and A-license designations. Many California dispensaries, cultivators, manufacturers, and distributors operate in exactly this structure — serving both medical patients and adult-use consumers, often on the same licensed premises.
The April 22 order creates a bifurcated federal schedule for these operators’ activities. Their M-licensed operations are now Schedule III. Their A-licensed operations remain Schedule I. They operate across two federal schedules simultaneously, with no precedent for this kind of split classification at the entity level.
Treasury has announced that forthcoming guidance will address expense apportionment — allocating costs between medical and adult-use activities, with only the former eligible for § 280E relief. From a regulatory compliance standpoint, dual operators need to examine their accounting systems immediately to determine:
- Whether revenue, payroll, inventory, and overhead are tracked separately by license type or commingled;
- Whether existing management agreements, intercompany allocations, or shared-service arrangements satisfy the “genuine separation” standard applied by the IRS and U.S. Tax Court;
- Whether entity structures put in place under prior 280E-minimization strategies remain optimal in a bifurcated Schedule III/Schedule I world;
- What additional documentation and accounting controls should be implemented now, before Treasury guidance issues, to ensure maximum defensibility.
Many California MSO structures were specifically architected to reduce 280E exposure through entity separation. Some of those structures may be redundant for the medical side of the business, or could inadvertently complicate expense allocation for the adult-use side. A comprehensive structural review — the kind of analysis that lives at the intersection of corporate law and regulatory compliance counsel — is not optional for California dual operators. It is urgent.
Capital Markets and Investment: What Investors Need to Know
The order has immediate implications for investors in California medical cannabis operations — both in ongoing cannabis M&A transactions and for those evaluating new positions.
Valuation and Cash Flow
The elimination of 280E for medical operators is the most direct valuation lever. For any California operator with meaningful M-license revenue, 280E removal translates directly to improved cash flow, stronger EBITDA, and lower effective tax rates. Verano Holdings, a major MSO, estimated that rescheduling would save it approximately $80 million annually in 280E expenses. California-specific operators and single-state businesses operate at different scale, but the directional impact is consistent: M-designated revenue streams are materially more valuable post-order than they were on April 21, 2026.
M&A Due Diligence Has Changed
The order “draws a line through the middle of the industry.” For California buyers and sellers in ongoing M&A processes, the regulatory compliance picture is fundamentally different for M-license positions than for A-license positions. Diligence on a California target that holds both designation types now requires separate analysis of each license category. As reflected in our Cannabis M&A Transactions practice, deals must now account for:
- The adequacy of the target’s M-license compliance infrastructure, since that license is now the gateway to DEA registration and 280E relief;
- Whether the target’s DCC license history is clean enough to support federal registration under the § 823 public-interest factors — a clean enforcement record is now a material deal term, not just a background diligence item;
- The DEA registration gap in change-of-control transactions. When a California cannabis business changes ownership, the DCC requires the new owner to submit all information under 4 CCR § 15003, including a background check, and the business may continue operating during the approval process. However, a change of ownership may affect the underlying state license status in ways that trigger the automatic DEA registration suspension provision — particularly if there is any period during which the DCC treats the existing license as having undergone a material change. Buyers and sellers must structure change-of-control provisions to address this risk, including whether responsibility for maintaining uninterrupted DEA registration vests with the seller, buyer, or is addressed through escrow or closing condition mechanics;
- Indemnification structures that explicitly address which party bears the risk if retroactive § 280E relief is or is not granted, and for which license categories.
Representations and warranties in cannabis M&A agreements must now be license-type-specific. A blanket representation that the company is in “regulatory compliance” is insufficient — it must distinguish M-license and A-license compliance postures, address DEA registration status, and account for the automatic suspension risk going forward.
Diligence Matrix for California Cannabis M&A Post-April 22
| Diligence Area | Key Question | Why It Matters Post-Order |
|---|---|---|
| State M-license status | Current, no pending enforcement actions? | Gateway to DEA registration and 280E relief |
| DCC enforcement history | Any prior suspensions, violations, or actions? | § 823 public-interest factor; DEA may deny registration |
| DEA registration | Filed within 60-day window? Status? | Determines whether Schedule III protections are live |
| Local permit status | Municipal approvals current? | Required for state license currency; triggers automatic suspension risk |
| License type allocation | Separate M/A cost center tracking? | Required for § 280E apportionment under Treasury guidance |
| Change-of-control mechanics | DCC approval timeline and DEA suspension risk? | Closing condition and indemnification structuring |
| Tax position | Prior-year 280E exposure; retroactive relief analysis? | Material to purchase price allocation and reps & warranties |
Banking: Improvement at the Margins
The cannabis banking problem has not been solved by rescheduling. Financial institutions remain subject to the Bank Secrecy Act and the 2014 FinCEN guidance, neither of which is eliminated by Schedule III status. Major banks are unlikely to fundamentally change their posture until the SAFER Banking Act passes or explicit federal safe harbors are legislated. For California cannabis investors and venture capital advisors evaluating debt-financed transactions, the practical takeaway is improved debt service capacity for medical operators and a somewhat more favorable lending environment at cannabis-specialist lenders — but not a transformed one.
Legal Risks: What Could Unwind This
The April 22 order is consequential, but not legally bulletproof. California operators and counsel should understand the primary vulnerabilities.
The Treaty Authority Question
The DOJ bypassed ordinary notice-and-comment rulemaking by invoking 21 U.S.C. § 811(d)(1). Legal commentators have noted that the order relies heavily on a 2024 Office of Legal Counsel opinion regarding treaty compliance — an interpretation not beyond challenge, particularly under the Supreme Court’s Loper Bright framework, which has increased judicial scrutiny of agency statutory interpretations. Whether the treaty-implementation authority extends to the full range of regulatory amendments accompanying the order — including new DEA registration requirements under 21 C.F.R. § 1301.13(k) — is a narrower but potentially significant legal question.
The order includes an express severability clause, acknowledging that individual provisions might be struck down without invalidating the whole. A registered operator who has affirmatively integrated into the federal framework is better positioned to argue for preservation of their status under a severability analysis than an operator who has not yet filed — another reason to act within the 60-day window.
The Ongoing Administrative Hearing
The expedited DEA hearing beginning June 29, 2026 will consider broader rescheduling of all marijuana. If that process results in comprehensive rescheduling, the adult-use gap closes and the current bifurcated structure becomes transitional. If the hearing produces delays — as the prior Biden-era process did — the two-tier system could persist for years, embedding competitive asymmetry between medical and adult-use operators. As analyzed in A Spring 2026 Field Report for California Cannabis Operators and Investors, the legal and market landscape is in genuine flux, and strategic decisions should be made with that uncertainty priced in.
Competitive Dynamics and the Illicit Market
One under-discussed consequence of partial rescheduling is its effect on California’s persistent illicit market problem. Licensed cultivators in California produced approximately 1.4 million pounds in 2024, while unlicensed operations produced an estimated 11.4 million pounds — a ratio that reflects the illicit market’s continued dominance, according to the DCC-commissioned ERA Economics report. The DCC’s head of enforcement has acknowledged the black market remains “very pervasive, and definitely larger than the legal market.”
By eliminating the 280E burden from licensed medical operators, rescheduling directly reduces one of the largest structural cost disadvantages that licensed operators face relative to the illicit market. The limitation, however, is that adult-use operators serve the far larger share of California’s consumer market and remain subject to 280E, limiting the aggregate competitive effect until broader rescheduling follows.
What California M-License Operators Must Do Now
This section is directed at California operators who hold active M-license designations — either as pure medical operators or as part of a dual M/A-license structure.
Immediate Actions (Next 60 Days):
- File your DEA registration application — by approximately June 22, 2026. This is the most time-sensitive action item. The 60-day window is the critical window for securing interim operating authority and a committed six-month DEA processing timeline. File a separate application for each licensed premises. Work with regulatory compliance counsel to assemble your DCC license documentation, confirm your license is current and in good standing, and assess your § 823 public-interest factor exposure before filing.
- Engage your tax counsel on 280E planning now. The effective date is January 1, 2026. Your accountant and tax attorney should immediately assess whether your entity structure, cost accounting systems, and expense tracking are positioned to capture the full benefit of post-280E deductibility. If you are a dual operator, this analysis must address expense apportionment between your medical and adult-use activities before Treasury guidance issues.
- Audit your DCC license compliance status. Federal registration automatically suspends if your California DCC license is suspended, revoked, or expires. Ensure all renewal filings, bond requirements, local permit renewals, and DCC compliance obligations are current. This is now a federal issue.
Near-Term Strategic Actions (Next 90–180 Days):
- Review your corporate structure. Many California operators built multi-entity structures specifically to mitigate 280E exposure — separating plant-touching and non-plant-touching entities, establishing management companies, and structuring brand licensing arrangements to shift deductible expenses upstream. Some of those structures may be redundant for the medical side of the business and may create unnecessary complexity in the new environment. A corporate restructuring review with both corporate counsel and regulatory compliance counsel is warranted.
- Revisit existing transaction documents. If you are party to a pending acquisition, earn-out, management agreement, or lease that was negotiated under the prior 280E economics, review it for provisions that need updating. Allocation of retroactive § 280E relief, representations about regulatory compliance, change-of-control triggers affecting DEA registration, and indemnification carve-outs are live issues in every California cannabis M&A transaction being negotiated today.
- Monitor the June 29 hearing. The outcome of the expedited DEA administrative hearing on broader rescheduling has direct implications for your competitive position, corporate structure, and transaction strategy. If adult-use cannabis moves to Schedule III through the hearing process, the calculus for restructuring and deal-making changes substantially.
The Bigger Picture for California
California was the first state to legalize medical cannabis in 1996 under the Compassionate Use Act, and it has operated the world’s largest legal cannabis market for nearly a decade. The state’s MAUCRSA framework, which created parallel M and A designation categories, inadvertently positioned California’s medical-designated operators as the first beneficiaries of federal rescheduling — provided they hold M-licenses and take the compliance steps required by the April 22 order.
The irony is not lost that adult-use operators — who serve by far the larger consumer segment in California — are excluded from the immediate order and continue under the crushing weight of Schedule I federal treatment. This creates a bifurcated competitive environment within the California market itself, with medical operators potentially achieving sustainable economics while adult-use operators continue under structurally punitive tax treatment. As anticipated in Marijuana Rescheduling, If It Happens, Will Be Incremental Progress — Still Not the Answer, rescheduling was never going to resolve every structural problem the California cannabis industry faces. But for California M-license operators who act quickly and competently, it is the most significant shift in federal cannabis law in a generation — and the compliance window is narrow.
This post is for informational purposes only and does not constitute legal advice or create an attorney-client relationship. If you hold a California cannabis license and have questions about how the DOJ’s rescheduling order affects your regulatory compliance obligations, corporate structure, or any pending transaction, contact the Law Office of Shay Aaron Gilmore for a consultation.